![]() In China, Arctic Vision is planning to initiate a Phase III clinical trial in the 2 nd half of the year.ĭr. ![]() In the U.S., Clearside's XIPERE New Drug Application filing was accepted in May 2021 by the Food and Drug Administration. The product is being investigated for the treatment of macular edema associated with uveitis ("UME"). ![]() Arctic Vision Logo (PRNewsfoto/Arctic Vision)ĪRVN001 is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS®) through Clearside's patented SCS Microinjector®.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |